Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.03
MYL's Cash to Debt is ranked lower than
55% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MYL: 0.03 )
MYL' s 10-Year Cash to Debt Range
Min: 0.02   Max: 44.56
Current: 0.03

0.02
44.56
Equity to Asset 0.22
MYL's Equity to Asset is ranked lower than
51% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MYL: 0.22 )
MYL' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.92
Current: 0.22

0.19
0.92
Interest Coverage 3.62
MYL's Interest Coverage is ranked higher than
51% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.14 vs. MYL: 3.62 )
MYL' s 10-Year Interest Coverage Range
Min: 0.83   Max: 9.19
Current: 3.62

0.83
9.19
F-Score: 6
Z-Score: 2.28
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.56
MYL's Operating margin (%) is ranked higher than
86% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. MYL: 16.56 )
MYL' s 10-Year Operating margin (%) Range
Min: 2.31   Max: 36
Current: 16.56

2.31
36
Net-margin (%) 12.36
MYL's Net-margin (%) is ranked higher than
84% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. MYL: 12.36 )
MYL' s 10-Year Net-margin (%) Range
Min: -3.53   Max: 30.52
Current: 12.36

-3.53
30.52
ROE (%) 28.67
MYL's ROE (%) is ranked higher than
96% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. MYL: 28.67 )
MYL' s 10-Year ROE (%) Range
Min: -8.33   Max: 21.55
Current: 28.67

-8.33
21.55
ROA (%) 6.20
MYL's ROA (%) is ranked higher than
82% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. MYL: 6.20 )
MYL' s 10-Year ROA (%) Range
Min: -2.47   Max: 18.43
Current: 6.2

-2.47
18.43
ROC (Joel Greenblatt) (%) 31.96
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. MYL: 31.96 )
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.11   Max: 92.62
Current: 31.96

4.11
92.62
Revenue Growth (3Y)(%) 1.90
MYL's Revenue Growth (3Y)(%) is ranked higher than
66% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. MYL: 1.90 )
MYL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.1   Max: 54.5
Current: 1.9

-6.1
54.5
EBITDA Growth (3Y)(%) 5.90
MYL's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. MYL: 5.90 )
MYL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20   Max: 107
Current: 5.9

-20
107
EPS Growth (3Y)(%) 32.40
MYL's EPS Growth (3Y)(%) is ranked higher than
89% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. MYL: 32.40 )
MYL' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.8   Max: 110.4
Current: 32.4

-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MYL Guru Trades in Q4 2013

David Dreman 1,221 sh (New)
Mario Gabelli 13,000 sh (unchged)
John Paulson 12,139,300 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Paul Tudor Jones Sold Out
Caxton Associates Sold Out
Steven Cohen 519,430 sh (-0.93%)
Scott Black 307,214 sh (-14.62%)
Joel Greenblatt 7,291 sh (-31.83%)
John Hussman 200,000 sh (-55.95%)
» More
Q1 2014

MYL Guru Trades in Q1 2014

Paul Tudor Jones 432,717 sh (New)
Andreas Halvorsen 1,776,108 sh (New)
Jean-Marie Eveillard 675,428 sh (New)
Louis Moore Bacon 134,160 sh (New)
Jim Simons 1,401,474 sh (New)
Steven Cohen 553,164 sh (+6.49%)
Mario Gabelli 13,000 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Joel Greenblatt Sold Out
David Dreman Sold Out
John Paulson 12,130,700 sh (-0.07%)
Scott Black 274,571 sh (-10.63%)
John Hussman 50,000 sh (-75%)
» More
Q2 2014

MYL Guru Trades in Q2 2014

Pioneer Investments 226,453 sh (New)
Jean-Marie Eveillard 1,241,991 sh (+83.88%)
Mario Gabelli 13,800 sh (+6.15%)
Vanguard Health Care Fund 4,775,700 sh (unchged)
John Paulson 12,130,700 sh (unchged)
John Hussman 50,000 sh (unchged)
Steven Cohen 83,700 sh (unchged)
Andreas Halvorsen Sold Out
Louis Moore Bacon 100,000 sh (-25.46%)
Scott Black 201,925 sh (-26.46%)
Jim Simons 652,200 sh (-53.46%)
Paul Tudor Jones 4,200 sh (-99.03%)
» More
Q3 2014

MYL Guru Trades in Q3 2014

Ray Dalio 57,106 sh (New)
Paul Tudor Jones 20,015 sh (+376.55%)
Louis Moore Bacon 435,000 sh (+335%)
Vanguard Health Care Fund 15,444,880 sh (+223.41%)
Pioneer Investments 282,805 sh (+24.88%)
John Paulson 12,494,700 sh (+3%)
John Hussman 50,000 sh (unchged)
Louis Moore Bacon 350,000 sh (unchged)
Steven Cohen Sold Out
Scott Black 199,406 sh (-1.25%)
Mario Gabelli 10,000 sh (-27.54%)
Jim Simons 465,200 sh (-28.67%)
Jean-Marie Eveillard 809,603 sh (-34.81%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-09-30 Add 223.41%1.24%$44.97 - $52.34 $ 57.5118%15444880
Jean-Marie Eveillard 2014-09-30 Reduce -34.81%0.06%$44.97 - $52.34 $ 57.5118%809603
Ray Dalio 2014-09-30 New Buy0.02%$44.97 - $52.34 $ 57.5118%57106
Mario Gabelli 2014-09-30 Reduce -27.54%$44.97 - $52.34 $ 57.5118%10000
Scott Black 2014-06-30 Reduce -26.46%0.4%$45.72 - $52.1 $ 57.5117%201925
Andreas Halvorsen 2014-06-30 Sold Out 0.36%$45.72 - $52.1 $ 57.5117%0
Jean-Marie Eveillard 2014-06-30 Add 83.88%0.07%$45.72 - $52.1 $ 57.5117%1241991
John Hussman 2014-03-31 Reduce -75%0.47%$42.26 - $57.2 $ 57.5120%50000
Andreas Halvorsen 2014-03-31 New Buy0.36%$42.26 - $57.2 $ 57.5119%1776108
Scott Black 2014-03-31 Reduce -10.63%0.16%$42.26 - $57.2 $ 57.5120%274571
Jean-Marie Eveillard 2014-03-31 New Buy0.09%$42.26 - $57.2 $ 57.5119%675428
Joel Greenblatt 2014-03-31 Sold Out 0.01%$42.26 - $57.2 $ 57.5119%0
David Dreman 2014-03-31 Sold Out $42.26 - $57.2 $ 57.5119%0
John Hussman 2013-12-31 Reduce -55.95%0.53%$37.865 - $44.5 $ 57.5140%200000
Scott Black 2013-12-31 Reduce -14.62%0.23%$37.865 - $44.5 $ 57.5140%307214
Joel Greenblatt 2013-12-31 Reduce -31.83%$37.865 - $44.5 $ 57.5140%7291
David Dreman 2013-12-31 New Buy$37.865 - $44.5 $ 57.5140%1221
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Mylan Inc

Scott Black’s Top First Quarter Holdings
Scott Black is the chairman, president, chief investment officer and founder of Boston-based Delphi Management, and is often featured in Barron’s. Delphi Management’s investment philosophy states that they “only invest in companies that meet our internally developed set of rigorous quantitative criteria.” The fund also only invests in equity securities of US-listed companies, and takes only long positions. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.70
MYL's P/E(ttm) is ranked higher than
84% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.00 vs. MYL: 24.70 )
MYL' s 10-Year P/E(ttm) Range
Min: 7.05   Max: 112.56
Current: 24.7

7.05
112.56
P/B 6.35
MYL's P/B is ranked higher than
59% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. MYL: 6.35 )
MYL' s 10-Year P/B Range
Min: 0.64   Max: 7.02
Current: 6.35

0.64
7.02
P/S 3.07
MYL's P/S is ranked higher than
76% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. MYL: 3.07 )
MYL' s 10-Year P/S Range
Min: 0.41   Max: 5.12
Current: 3.07

0.41
5.12
PFCF 36.17
MYL's PFCF is ranked higher than
87% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 36.17 )
MYL' s 10-Year PFCF Range
Min: 8.81   Max: 82
Current: 36.17

8.81
82
EV-to-EBIT 23.86
MYL's EV-to-EBIT is ranked higher than
82% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. MYL: 23.86 )
MYL' s 10-Year EV-to-EBIT Range
Min: -10.7   Max: 28.8
Current: 23.86

-10.7
28.8
PEG 3.49
MYL's PEG is ranked higher than
86% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 3.49 )
MYL' s 10-Year PEG Range
Min: 0.37   Max: 11.64
Current: 3.49

0.37
11.64
Shiller P/E 47.56
MYL's Shiller P/E is ranked higher than
82% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 165.76 vs. MYL: 47.56 )
MYL' s 10-Year Shiller P/E Range
Min: 10.98   Max: 701
Current: 47.56

10.98
701
Current Ratio 1.30
MYL's Current Ratio is ranked higher than
55% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. MYL: 1.30 )
MYL' s 10-Year Current Ratio Range
Min: 1.3   Max: 8.52
Current: 1.3

1.3
8.52
Quick Ratio 0.92
MYL's Quick Ratio is ranked higher than
54% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. MYL: 0.92 )
MYL' s 10-Year Quick Ratio Range
Min: 0.85   Max: 6.76
Current: 0.92

0.85
6.76

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.46
MYL's Price/DCF (Projected) is ranked higher than
85% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.02 vs. MYL: 2.46 )
MYL' s 10-Year Price/DCF (Projected) Range
Min: 0.62   Max: 2.51
Current: 2.46

0.62
2.51
Price/Median PS Value 1.67
MYL's Price/Median PS Value is ranked higher than
62% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. MYL: 1.67 )
MYL' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.73
Current: 1.67

0.36
3.73
Price/Peter Lynch Fair Value 2.57
MYL's Price/Peter Lynch Fair Value is ranked higher than
90% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYL: 2.57 )
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67   Max: 10.2
Current: 2.57

0.67
10.2
Earnings Yield (Greenblatt) 4.20
MYL's Earnings Yield (Greenblatt) is ranked higher than
81% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MYL: 4.20 )
MYL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 15.1
Current: 4.2

3.5
15.1
Forward Rate of Return (Yacktman) 12.17
MYL's Forward Rate of Return (Yacktman) is ranked higher than
81% of the 497 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. MYL: 12.17 )
MYL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.6   Max: 39.2
Current: 12.17

3.6
39.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MYL.Germany, MYL.Switzerland,
Mylan Inc was incorporated in Pennsylvania in 1970. The Company together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company offers 1,300 marketed products, to customers in 140 countries and territories. It also operates a research and development network that delivers a robust product pipeline. Additionally, the Company has a specialty business that is engaged in the respiratory and allergy therapies. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids while engaging on those products that are difficult to formulate and manufacture, and typically have longer life cycles than traditional generic pharmaceuticals, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. In addition, it offers antiretroviral therapies upon which HIV/AIDS patients in developing countries depend. The Company operates in two segments, Generics and Specialty. The generic pharmaceutical business is conducted primarily in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages in the development, manufacture and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
Scott Black’s Top First Quarter Holdings Apr 23 2014 
Should You Buy Actavis? Mar 18 2014 
Scott Black’s Top Five Stocks at Year End Jan 09 2014 
Scott Black’s Top Five Third Quarter Holdings Oct 22 2013 
S&P Winners Broadly Held by Billionaires Oct 06 2013 
Weekly CEO Sells Highlight: Workday Inc., Kirby Corp., Mylan Inc., Infinera Corporation Sep 09 2013 
Three Stocks for a Recovering Europe Jul 29 2013 
comment on MYL Jan 03 2013 


More From Other Websites
How traders are protecting Mylan Dec 19 2014
Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference Dec 17 2014
Mylan to Present at the J.P. Morgan 33rd Annual Healthcare Conference Dec 17 2014
Teva Upgraded On Strength Of Copaxone MS Drug Dec 12 2014
MiMedx Group, Conn's, Mylan, Pfizer and Amgen highlighted as Zacks Bull and Bear of the Day Dec 12 2014
Mylan Among First to Launch Generic Celebrex Dec 11 2014
Teva Pharm sees 2015 revenue lower than forecast Dec 11 2014
Mylan Launches Generic Robaxin® Injection Dec 11 2014
Mylan Launches First Generic Version of Orapred ODT® Dec 11 2014
Mylan Launches Generic Robaxin® Injection Dec 11 2014
Mylan Launches First Generic Version of Orapred ODT® Dec 11 2014
Mylan pays bonuses to ease 'spinversion' Dec 10 2014
Mylan Launches One of First Available Generic Versions of Celebrex® Capsules Dec 10 2014
Merck-Cubist Deal Is On Despite Patent Setback Dec 09 2014
Two Gauges That Point To Fund Buying In A Stock Dec 08 2014
World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017 Dec 08 2014
World TeamTennis and Mylan Announce Title Sponsorship Extension Through 2017 Dec 08 2014
Medical Issues Keep Climbing Into Sell Zone Dec 04 2014
GlaxoSmithKline scraps £7bn sale of old drugs Dec 04 2014
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through... Dec 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK